Application of koumine and koumine homolog in preparation of medicines for treating diabetic complications
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of kelkinin and diabetes, which is applied in the field of medicine to achieve a large therapeutic window, no tolerance and addiction, and the effect of improving neuropathy
Active Publication Date: 2014-04-02
FUJIAN MEDICAL UNIV
View PDF5 Cites 3 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
There is no literature report on the effect of kinesin on the treatment of diabetic complications and its possible use
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0026] Improvement of hyperalgesia in diabetic rats by subcutaneous injection of kelkinin in the back of the neck.
[0027] 1.1 Drugs and reagents:
[0028] Gelkinin is extracted, separated and purified from the natural plant Gelkins by the applicant of the present invention, see Patent No.: 200810071469.9, the title of the invention is "Method for Separating and Preparing Gelkins Alkaloid Monomers from Gelkins by High-speed Countercurrent Chromatography" and Patent No. 2011101746576 The disclosed technology is the prior art with a purity of >98.5% (precisely weigh kelkinin, dissolve it with 1mol / l HCl, dilute it with normal saline, adjust the pH (4
[0029] 1.2 Animals: ...
Embodiment 2
[0042] Improvement of nerve conduction impairment in diabetic rats by subcutaneous injection of kelezin in the back of the neck.
[0043] 2.1 Drugs and reagents:
[0044] Kiskinin is obtained by the applicant of the present invention by extracting, separating and purifying the natural plant Gelkins, with a purity of >98.5% (accurately weigh kelkinin, dissolve it with 1mol / l HCl, dilute with normal saline, adjust the pH with 1mol / l NaOH (4
[0045] 2.2 Animals:
[0046] SD rats, male, 180-220g, provided by Shanghai Slack Animal Center. They were raised at room temperature at 25°C under a light-dark cycle of 12 / 12h, free to eat and drink, and used for formal experiments after 3 days of adaptation to t...
Embodiment 3
[0057] Improvement of neurofiber pathology in diabetic rats by subcutaneous injection of kelkinin in the back of the neck.
[0058] 3.1 Drugs and reagents:
[0059] Kiskinin is obtained by the applicant of the present invention by extracting, separating and purifying the natural plant Gelkins, with a purity of >98.5% (accurately weigh kelkinin, dissolve it with 1mol / l HCl, dilute with normal saline, adjust the pH with 1mol / l NaOH (4
[0060] 3.2 Animals:
[0061] SD rats, male, 180-220g, provided by Shanghai Slack Animal Center. They were raised at room temperature at 25°C under a light-dark cycle of 12 / 12h, free to eat and drink, and used for formal experiments after 3 days of adaptation to the lab...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention discloses an application of koumine and koumine homolog in the preparation of medicines for treating diabetic complications. The koumine is high in therapeutic index, the therapeutic index of the koumine for treating the pain hypersensitivity of diabetic rats is estimated to reach 4762, the koumine can be used for obviously improving the neuropathy of the diabetic rats, the details are explained in the embodiment 1, and the koumine is large in safe therapeutic window and suitable for the preparation of the medicines for treating the diabetic complications, is likely to have no tolerance or addiction, and has low side effects, and therefore, the koumine has potentially great economic effect. The koumine and the koumine homolog or pharmaceutically acceptable salts of the koumine can be applied to the preparation of the medicines for treating the diabetic complications, have no disadvantages of two types of clinically frequently-used medicines for treating the diabetic complications, are developed and researched according to national specifications about innovative drug examination and approval and are expected to be prepared into the novel national class-1 medicines for treating the diabetic complications which are capable of effectively treating the diabetic complications, have small side effects, clear industrialization prospect, no tolerance and no addiction and possess the national proprietary intellectual property rights.
Description
technical field [0001] The invention belongs to the field of medicine, and relates to the application of koumine alkaloid monomers, in particular to the application of koumine and its homologues in the preparation of medicines for treating diabetic complications. Background technique [0002] Complications of diabetes include diabetic neuropathy and pain, among others. Among them, diabetic neuropathy is the most common, which can affect the central and peripheral nerves, especially distal sensory neuropathy, which accounts for more than 50% of all diabetic neuropathies. The specific symptoms are hyperalgesia, decreased peripheral nerve conduction velocity, and nerve fiber degeneration. etc. seriously affect the quality of life. Drug therapy is currently one of the main means of clinically treating patients with diabetic complications, and gabapentin is currently the first-line drug for treating diabetic peripheral neuropathy. As of 2011, there were 366 million diabetic pat...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more